Brief: FDA Removes Partial Clinical Hold On TakeAim Leukemia Study RP2D Established At 300 Mg BID

Curis

06/07/2023 13:14

July 6 (Reuters) - Curis Inc  CRIS.O :
    * FDA REMOVES PARTIAL CLINICAL HOLD ON TAKEAIM LEUKEMIA
STUDY RP2D
ESTABLISHED AT 300 MG BID
    * CURIS INC: RECOMMENDED PHASE 2 DOSE (RP2D) FOR EMAVUSERTIB
AS A
MONOTHERAPY HAS BEEN ESTABLISHED AT 300 MG BID IN PATIENTS AML
OR MDS
    * CURIS INC: ALSO PLAN TO INITIATE A FRONT-LINE COMBINATION
STUDY
OF EMAVUSERTIB WITH AZACITIDINE AND VENETOCLAX
    * CURIS INC: IN 2024, WE EXPECT TO HAVE UPDATED DATA FROM
TAKEAIM
LEUKEMIA MONOTHERAPY STUDY

Source text for Eikon:  ID:nPn59k2Bza 
Further company coverage:  CRIS.O 

 ((reuters.briefs@thomsonreuters.com;))